Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Elenore P. Bhatraju, Andrea C. Radick, Brian G. Leroux, Theresa W. Kim, Jeffrey H. Samet & Judith I. Tsui. (2023) Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder. The American Journal of Drug and Alcohol Abuse 49:4, pages 511-518.
Read now
Read now
Eric P. Borrelli, Jeffrey Bratberg, Benjamin D. Hallowell & Stephen J. Kogut. (2023) Benzodiazepine Dose Intensity among Patients Concurrently Prescribed Buprenorphine in Rhode Island. Substance Use & Misuse 58:8, pages 1038-1045.
Read now
Read now
Frank D. Buono, Rosemary Pickering, Rebecca Berlepsch & Shelley Halligan. (2022) Percutaneous electrical nerve field stimulation to reduce clinical opiate withdrawal: a case series. Journal of Substance Use 27:5, pages 501-504.
Read now
Read now
Md Mahmudul Hasan, Md. Noor-E-Alam, Jiesheng Shi, Leonard D. Young & Gary J. Young. (2022) Long-term patient outcomes following buprenorphine/naloxone treatment for opioid use disorder: a retrospective analysis in a commercially insured population. The American Journal of Drug and Alcohol Abuse 48:4, pages 481-491.
Read now
Read now
Fulton F Velez, Sam Colman, Laura Kauffman, Charles Ruetsch, Kathryn Anastassopoulos & Yuri A Maricich. (2021) Comparison of Healthcare Resource Utilization Between Patients Who Engaged or Did Not Engage With a Prescription Digital Therapeutic for Opioid Use Disorder. ClinicoEconomics and Outcomes Research 13, pages 909-916.
Read now
Read now
Fulton F Velez, Sam Colman, Laura Kauffman, Kathryn Anastassopoulos, Sean Murphy & Yuri Maricich. (2021) Real-world changes in US health system hospital-based services following treatment with a prescription digital therapeutic for opioid use disorder. Hospital Practice 49:5, pages 341-347.
Read now
Read now
Fulton F. Velez, Hilary F. Luderer, Robert Gerwien, Benjamin Parcher, Dylan Mezzio & Daniel C. Malone. (2021) Evaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorder. Postgraduate Medicine 133:4, pages 421-427.
Read now
Read now
Yuri A. Maricich, Xiaorui Xiong, Robert Gerwien, Alice Kuo, Fulton Velez, Bruce Imbert, Keely Boyer, Hilary F. Luderer, Stephen Braun & Karren Williams. (2021) Real-world evidence for a prescription digital therapeutic to treat opioid use disorder. Current Medical Research and Opinion 37:2, pages 175-183.
Read now
Read now
Weijia Wang, Nicole Gellings Lowe, Ali Jalali & Sean M. Murphy. (2021) Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder. Journal of Medical Economics 24:1, pages 61-68.
Read now
Read now
Articles from other publishers (41)
Nazila Jamshidi, Akshay Athavale, Christopher Tremonti, Catherine McDonald, Shanmugam Banukumar, Santiago Vazquez, Natasha Luquin, Marina Santiago & Bridin Murnion. (2022) Evaluation of adherence monitoring in buprenorphine treatment: A pilot study using timed drug assays to determine accuracy of testing. British Journal of Clinical Pharmacology 89:7, pages 1938-1947.
Crossref
Crossref
Michael Curtis, Anna L Wilkinson, Paul Dietze, Ashleigh Cara Stewart, Stuart A Kinner, Reece David Cossar, Emily Nehme, Campbell Aitken, Shelley Walker, Tony Butler, Rebecca J Winter, Karen Smith & Mark Stoove. (2023) Prospective study of retention in opioid agonist treatment and contact with emergency healthcare following release from prisons in Victoria, Australia. Emergency Medicine Journal 40:5, pages 347-354.
Crossref
Crossref
Krista R. Noam, Timothy J. Schmutte, Sandrine Pirard, Carol Bourdon, Daniel Langless & Robert Plant. (2023) Associations Between Inpatient Induction on Medications for Opioid Use Disorder and Postdischarge Medications for Opioid Use Disorder Adherence, Overdose, and Service Use. Journal of Addiction Medicine 17:3, pages e199-e201.
Crossref
Crossref
Stephen C. Ijioma, Howard D. Chilcoat & Angela M. DeVeaugh-Geiss. (2023) Oral buprenorphine utilization, concomitant benzodiazepines and opioid analgesics, and payment source: Trends from 2015 to 2019. Journal of Substance Use and Addiction Treatment 147, pages 208980.
Crossref
Crossref
Michael Curtis, Anna L. Wilkinson, Paul Dietze, Ashleigh C. Stewart, Stuart A. Kinner, Rebecca J. Winter, Campbell Aitken, Shelley J. Walker, Reece D. Cossar, Tony Butler & Mark Stoové. (2023) Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study. Harm Reduction Journal 20:1.
Crossref
Crossref
Christian Heidbreder, Paul J. Fudala & Mark K. Greenwald. (2023) History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder. Drug and Alcohol Dependence Reports 6, pages 100133.
Crossref
Crossref
Hilary Luderer, Nicole Enman, Robert Gerwien, Stephen Braun, Samantha McStocker, Xiaorui Xiong, Carrington Koebele, Christopher Cannon, Joseph Glass & Yuri Maricich. (2023) A Prescription Digital Therapeutic to Support Unsupervised Buprenorphine Initiation for Patients With Opioid Use Disorder: Protocol for a Proof-of-Concept Study. JMIR Research Protocols 12, pages e43122.
Crossref
Crossref
Albert J. Burgess-Hull, Caleb Brooks, David H. Epstein, Devang Gandhi & Enrique Oviedo. (2023) Using Machine Learning to Predict Treatment Adherence in Patients on Medication for Opioid Use Disorder. Journal of Addiction Medicine 17:1, pages 28-34.
Crossref
Crossref
Wellington Kanyongo & Absalom E. Ezugwu. (2023) Feature selection and importance of predictors of non-communicable diseases medication adherence from machine learning research perspectives. Informatics in Medicine Unlocked 38, pages 101232.
Crossref
Crossref
Gabriel G. Edwards, Ayako Miyashita-Ochoa, Enrico G. Castillo, David Goodman-Meza, Ippolytos Kalofonos, Raphael J. Landovitz, Arleen A. Leibowitz, Craig Pulsipher, Ed El Sayed, Steven Shoptaw, Chelsea L. Shover, Michelle Tabajonda, Yvonne S. Yang & Nina T. Harawa. (2022) Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine. AIDS and Behavior 27:1, pages 10-24.
Crossref
Crossref
Benjamin D. Hallowell, Laura C. Chambers, Elizabeth A. Samuels, Jeffrey Bratberg, James McDonald, Adam Nitenson, Collette Onyejekwe & Francesca L. Beaudoin. (2022) Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population. Drug and Alcohol Dependence 241, pages 109680.
Crossref
Crossref
Erin L. Winstanley, Emily P. Thacker, Lyn Yuen Choo, Laura R. Lander, James H. Berry & Babak Tofighi. (2022) Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use. Drug and Alcohol Dependence Reports 5, pages 100091.
Crossref
Crossref
Celine M. Laffont, Eliford Ngaimisi, Mathangi Gopalakrishnan, Vijay Ivaturi, Malcolm Young, Mark K. Greenwald & Christian Heidbreder. (2022) Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder. Frontiers in Pharmacology 13.
Crossref
Crossref
Leen Naji, Tea Rosic, Nitika Sanger, Brittany Dennis, Alannah Hillmer, Jacqueline Hudson, Andrew Worster, James Paul, David C. Marsh, Lehana Thabane & Zainab Samaan. (2022) Cannabis use and opioid relapse: An exploratory survival analysis of prospectively collected data. Frontiers in Psychiatry 13.
Crossref
Crossref
Michelle M. Zuccarini & Cate Stiller. (2022) The Effect of Peer Support on Treatment Engagement for Opioid Use Disorder. Journal of the American Psychiatric Nurses Association, pages 107839032211280.
Crossref
Crossref
Delesha Carpenter, Katie V. Lambert, J. Chase Harless, Courtenay Gilmore Wilson, Scott A. Davis, William A. Zule & Bayla Ostrach. (2022) North Carolina community pharmacists’ buprenorphine dispensing practices and attitudes. Journal of the American Pharmacists Association 62:5, pages 1606-1614.
Crossref
Crossref
Fulton F. Velez, Kathryn P. Anastassopoulos, Samuel Colman, Neel Shah, Laura Kauffman, Sean M. Murphy, Charles Ruetsch & Yuri A. Maricich. (2022) Reduced Healthcare Resource Utilization in Patients with Opioid Use Disorder in the 12 Months After Initiation of a Prescription Digital Therapeutic. Advances in Therapy 39:9, pages 4131-4145.
Crossref
Crossref
Hillary Samples, Arthur Robin Williams, Stephen Crystal & Mark Olfson. (2022) Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes. Journal of Substance Abuse Treatment 139, pages 108774.
Crossref
Crossref
Scott A. Simpson, Melissa Hordes, Joshua Blum, Deborah Rinehart & Alia Al-Tayyib. (2022) Barriers to Engagement in Opioid Use Disorder Treatment After Buprenorphine Induction. Journal of Addiction Medicine 16:4, pages 479-482.
Crossref
Crossref
Rachel Lynn Graves, Jeanmarie Perrone, Mohammed Ali Al-Garadi, Yuan-Chi Yang, Jennifers Love, Karen O’Connor, Graciela Gonzalez-Hernandez & Abeed Sarker. (2022) Thematic Analysis of Reddit Content About Buprenorphine-naloxone Using Manual Annotation and Natural Language Processing Techniques. Journal of Addiction Medicine 16:4, pages 454-460.
Crossref
Crossref
Leslie Cole, Alina Cernasev, Katie Webb, Santosh Kumar & A. Shaun Rowe. (2022) A Study of the MTHFR Gene Prevalence in a Rural Tennessee Opioid Use Disorder Treatment Center Population. International Journal of Environmental Research and Public Health 19:6, pages 3255.
Crossref
Crossref
Alene Kennedy-Hendricks, Cameron J. Schilling, Alisa B. Busch, Elizabeth A. Stuart, Haiden A. Huskamp, Mark K. Meiselbach, Colleen L. Barry & Matthew D. Eisenberg. (2021) Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder. Journal of General Internal Medicine 37:4, pages 769-776.
Crossref
Crossref
Marian Wilson, Tamara Odom-Maryon, Karen Stanek, Trevor Roush, Joseph Muriungi, Alvina Jesse, Raymond M. Quock & Matthew Layton. (2022) Hyperbaric Oxygen to Assist Adults With Opioid Use Disorder in Reducing Methadone Dose. Journal of Addictions Nursing 33:1, pages 27-36.
Crossref
Crossref
Md Mahmudul Hasan, Gary J. Young, Jiesheng Shi, Prathamesh Mohite, Leonard D. Young, Scott G. Weiner & Md. Noor-E-Alam. (2021) A machine learning based two-stage clinical decision support system for predicting patients’ discontinuation from opioid use disorder treatment: retrospective observational study. BMC Medical Informatics and Decision Making 21:1.
Crossref
Crossref
Md Mahmudul Hasan, Md. Noor-E-Alam, Prathamesh Mohite, Md Saiful Islam, Alicia Sasser Modestino, Alyssa M. Peckham, Leonard D. Young & Gary J. Young. (2021) Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts. Journal of Substance Abuse Treatment 131, pages 108416.
Crossref
Crossref
Spencer Andrews, Cara DeAngelis, Somayeh Hooshmand, Neysha Martinez-Orengo & Melissa Zajdel. (2021) Reducing Emergency Department Visits and Opioid-Related Deaths in Maryland. Journal of Science Policy & Governance 18:04.
Crossref
Crossref
Rachel Mosher HenkeMichael A. HeadJessica Camacho-CookJanice R. LinChristopher D. Carroll. (2021) Cost Offsets of Treatment for Serious Mental Illness and Substance Use Disorder. Psychiatric Services 72:9, pages 1006-1011.
Crossref
Crossref
Tyler J. Varisco, Susan Abughosh, Hua Chen, Sang Kyu Cho, Marc L. Fleming, Douglas Ziedonis & Douglas Thornton. (2021) Switching pharmacies leads to gaps in medication possession in individuals treated with buprenorphine. Journal of the American Pharmacists Association 61:5, pages 589-595.
Crossref
Crossref
Mark K. Greenwald, Tabitha E.H. Moses & Timothy A. Roehrs. (2021) At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities. Translational Research 234, pages 58-73.
Crossref
Crossref
Richard J. Bodnar. (2021) Endogenous opiates and behavior: 2019. Peptides 141, pages 170547.
Crossref
Crossref
Erin FerriesPatrick RacsaBrock BizzellClay RhodesBrandon Suehs. (2021) Removal of prior authorization for medication-assisted treatment: impact on opioid use and policy implications in a Medicare Advantage population. Journal of Managed Care & Specialty Pharmacy 27:5, pages 596-606.
Crossref
Crossref
Evan S. Cole, Coleman Drake, Ellen DiDomenico, Michael Sharbaugh, Joo Yeon Kim, Dylan Nagy, Gerald Cochran, Adam J. Gordon, Walid F. Gellad, Janice Pringle, Jack Warwick, Chung-Chou H. Chang, Julie Kmiec, David Kelley & Julie M. Donohue. (2021) Patterns of clinic switching and continuity of medication for opioid use disorder in a Medicaid-enrolled population. Drug and Alcohol Dependence 221, pages 108633.
Crossref
Crossref
Kangho Suh, Anirban Basu, Josh J. Carlson & Kelley R. Branch. (2020) Exploring Medication Adherence with P2Y12 Inhibitors Using Conditional and Unconditional Quantile Regression Approaches. American Journal of Cardiovascular Drugs 21:2, pages 193-204.
Crossref
Crossref
Kathleen T. Brady, Frances R. Levin, Marc Galanter & Herbert D. KleberJenna McCauley & A. McLellan. 2021. The American Psychiatric Association Publishing Textbook of Substance Use Disorder Treatment. The American Psychiatric Association Publishing Textbook of Substance Use Disorder Treatment.
Zoe M. Weinstein & Honora Englander. 2021. Treating Opioid Use Disorder in General Medical Settings. Treating Opioid Use Disorder in General Medical Settings
43
56
.
Jill S. Warrington, Gregory S. Warrington, Samuel Francis-Fath & John Brooklyn. (2020) Urinary Buprenorphine, Norbuprenorphine and Naloxone Concentrations and Ratios: Review and Potential Clinical Implications. Journal of Addiction Medicine 14:6, pages e344-e349.
Crossref
Crossref
Lia N. Pizzicato, Jeffrey K. Hom, Monica Sun, Caroline C. Johnson & Kendra M. Viner. (2020) Adherence to buprenorphine: An analysis of prescription drug monitoring program data. Drug and Alcohol Dependence 216, pages 108317.
Crossref
Crossref
Hillary SamplesArthur Robin WilliamsStephen CrystalMark Olfson. (2020) Impact Of Long-Term Buprenorphine Treatment On Adverse Health Care Outcomes In Medicaid. Health Affairs 39:5, pages 747-755.
Crossref
Crossref
Heather B. Ward, Matthew J. Mosquera, Joji Suzuki & Timothy Y. Mariano. (2020) A Systematic Review of Noninvasive Brain Stimulation for Opioid Use Disorder. Neuromodulation: Technology at the Neural Interface 23:3, pages 301-311.
Crossref
Crossref
Walter Ling, Vijay R. Nadipelli, Caitlyn T. Solem, Naoko A. Ronquest, Yu-Chen Yeh, Susan M. Learned, Vishaal Mehra & Christian Heidbreder. (2020) Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study. Journal of Substance Abuse Treatment 110, pages 1-8.
Crossref
Crossref
Alex J. Luli, Mark Bounthavong & Jonathan H. Watanabe. (2020) Pharmacists on the front-line of solving a public health crisis: Increasing access to medications for opioid use disorder. Journal of the American Pharmacists Association 60:2, pages 297-303.
Crossref
Crossref